DOCSLIB.ORG

Research Report Biotechnology Companies

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Research Report Biotechnology Companies Research Report Biotechnology Companies 8/29/17 Research and Development 1 100X Imaging India Pvt Ltd Bio-medical devices and instruments Karnataka 2 Abexome Biosciences Health-care Karnataka Private Ltd 3 ABL Biotechnologies Ltd Marine Biotechnology, Biochemicals Tamil Nadu 4 ABLE ( Association of Biotechnology Karnataka Biotechnology Led Enterprises) 5 Abott India Pharmaceuticals Maharashtra 6 ABS – NOVACELL Bio Health Care Andhra Pradesh Pharmaceuticals INDIA PVT LTD 7 Accelrys Inc. Bioinformatics,Services, Software Karnataka Tools 8 Accurex Biomedical Pvt Ltd Healthcare, Diagnostics Maharashtra 9 Accutest Research Services, Contract Research Maharashtra Laboratories (I) Pvt Ltd Organization 10 Ace Biomed Private Services, Contract Research Maharashtra Limited Organization 11 Ace Instruments & Services Services, Equipment, Instruments and Maharashtra Pvt. Ltd Media 12 Actimus Biosciences Pvt Services, Contract Research Andhra Pradesh Ltd Organization 13 Actis Biologics Pvt. Ltd. Healthcare, Recombinant Maharashtra Therapeutics 14 Acton Biotech (India) Pvt. Healthcare, Pharmacogenomics Maharastra Ltd 15 Adam Fabriwerk Pvt Ltd Services, Equipment, Instruments and Maharashtra Media 16 Advanced Bio-Photonics Services, Equipment, Instruments and Tamil Nadu Media 17 Advanced Computer Bioinformatics,Services, Software Uttar Pradesh Systems Tools 18 Advanced Enzyme Process Industries,Enzymes Maharashtra Technologies Ltd 19 Advanced Microdevices Services, Equipment, Instruments and Haryana Pvt Ltd Media 20 Advanta India Ltd Agriculture, Hybrid Seeds Andhra Pradesh 21 Advinus Therapeutics Ltd. Healthcare, Biotherapeutics Maharastra 22 AG Bioteck Laboratories Agriculture, Biofertilizers and Andhra Pradesh (India) Ltd Biopesticides, Plant Tissue Culture 23 Agappe Diagnostics Pvt Ltd Healthcare, Diagnostics Kerala 24 Agastya Biopharm India Pharma, Agri Biotechnology, Ecology Kerala Ltd & Environmental Engineering 25 Agharkar Research Research Institute / Animal Sciences, Maharashtra Institute Plant Sciences, Microbial Science 26 Agilent Technologies India Services, Equipment, Instruments New Delhi Pvt Ltd and Media 27 Agro Biotech Research Agriculture, Biofertilizers and Kerala Centre Ltd Biopesticides 28 Agro Machinery & Agriculture Kerala Consultancy (p) Ltd. 29 Ajanta Pharma Limited Healthcare, Antibiotics, Maharashtra Nutraceuticals. 30 Ajay Biotech India Ltd Agriculture, Biofertilizers and Maharashtra Biopesticides 31 Ajeet Seeds Ltd Agriculture, Hybrid Seeds Maharashtra 32 Alcon Biosciences Private Pharmaceutical Manufacturers Maharashtra Limited 33 Alembic Ltd Animal Biotechnology, Healthcare, Gujarat Antibiotics, Nutraceuticals; Pharma 34 Alfa Laval India Ltd Services, Equipment, Instruments and Maharashtra Media 35 Alkali Metals Ltd. Industrial products and processes Andhra Pradesh 36 All India Biotech Associations, Biotech Associations New Delhi Association 37 Allele Life Sciences (P) Ltd. Agriculture / Environmental Uttar Pradesh biotechnology, Biotechnology 38 Allied Univet Marketers Pet foods, Cosmetics, Tamil Nadu Pvt. Ltd Pharmaceuticals, Herbal Remedies & Tonics & Marketing. 39 Amar Immunodiagnostics Healthcare, Diagnostics Andhra Pradesh Pvt Ltd 40 Ambalal Sarabhai Healthcare, Antibiotics Gujarat Enterprise 41 Americos Industries Inc. Process Industries, Enzymes Gujarat 42 Amit Biotech Agriculture, Biofertilizers and West Bengal Biopesticides 43 Amkette Analytics Pvt Ltd Services, Equipment, Instruments and Maharashtra Media 44 Amrita Therapeutics Health-care Gujarat Limited 45 Anand Brothers & AB Healthcare, Diagnostics New Delhi Diachem Systems Pvt Ltd 46 ANDEL Equipment Pvt Ltd Services, Equipment, Instruments and Punjab Media 47 ANIL Group Process Industries, Enzymes Gujarat 48 Anil Products Ltd. Manufacturing Gujarat 49 Animal Biotech Bangalore Development of products for Animal Karnataka Pvt Ltd Health and Consultancy in Biopharmaceutical 50 Ankur Seeds Pvt Ltd Agriculture, Hybrid Seeds,Transgenic Maharashtra Plants 51 Anthem Bio-Sciences Pharmaceutical, Biotechnology, Karnataka Pvt.Ltd Agriculture chemicals, Material Science 52 Apothecaries Pvt Ltd Clinical Trials services New Delhi 53 Apticraft Systems (P) Ltd Bioinformatics, Contract Research Madhya Pradesh Organization, Software Tools 54 Laurus Labs Pvt. Ltd Healthcare Andhra Pradesh 55 ABC Genomics (India) Pvt. Health-care Uttar Pradesh Ltd 56 ARA Healthcare Pvt Ltd Health-care Haryana 57 Aris Global Services, Contract Research Karnataka Organization 58 Aristogene Biosciences Biotechnology Karnataka 59 Arjuna Natural Extracts Ltd Healthcare, Herbal Extracts Kerala 60 Arun & Co. Process Industries, Enzymes Maharashtra 61 Arvind Remedies Ltd Healthcare Tamil Nadu 62 Ashco Niulab Industries Healthcare, Clinical Trials Maharashtra Ltd. 63 Asian Clinical Trials Ltd Healthcare,Services, Contract Andhra Pradesh Research Organization, Clinical Trials 64 Asiatic Clinical Research Clinical Research Karnataka 65 Astra Zeneca India Pvt Ltd Healthcare, Recombinant Karnataka Therapeutics, Diagnostics 66 Atharva Biosciences Pvt Healthcare, Diagnostics New Delhi Ltd 67 Atharva Lifesciences Healthcare Consultancy Karnataka Consulting Pvt. Ltd. 68 Aumgene Biosciences Pvt. Pharmaceutical, biotechnology Gujrat Ltd 69 Aureole Technologies Pvt Health-care Karnataka Ltd. 70 Aurigene Discovery Pharma/ Biotech/Clinical Research, Karnataka Technologies Limited Healthcare, Medical, R&D 71 Auroprobe Laboratories Healthcare, New Delhi 72 Automed Systems Private Services, Equipment, Instruments and Karnataka Ltd Media 73 Aventis Pharma Ltd Healthcare Maharashtra 11. Subsector Vaccines, Recombinant Therapeutics, Recombinant Therapeutics,Vaccines 74 Avesthagen Limited Plant Biotechnology Karnataka Microbial and Cell Biotechnology, science and innovation, biopharmaceuticals, bionutrition, and bioagriculture 75 Avigna Chemitech Pvt. Ltd Pharmaceuticals Karnataka 76 Avon Organics Ltd Healthcare,Process Industries Andhra Pradesh 77 Avra Laboratories Pvt Ltd Services, Contract Research Andhra Pradesh Organization 78 AVT Biotech Agriculture, Plant Tissue Culture Kerala 79 Axiom Biotek INC Pharmaceutical Science and Animal New Delhi Science 80 Axis Diagnostics & Biotech Healthcare, Diagnostics Haryana Ltd 81 Axygen Scientific Pvt Ltd Services, Equipment, Instruments and Himachal Pradesh Media 82 Ayan India Distribution N/A Rajasthan Private Limited [new company under incorporation – MCA SRN A75319707] 83 Ayushi Biotech Healthcare Gujarat 84 Azadi Bio Science Pvt. Ltd Agree Seeds & Services Gujarat 85 BACFO Pharmaceuticals Healthcare, Herbal Extracts New Delhi India Limited 86 Bacto Agro Culture Care Agriculture, Biofertilizers and Tamil Nadu Pvt Ltd Biopesticides 87 Bafna Pharmaceuticals Pharmaceuticals Tamilnadu 88 Bangalore Genei Pvt Ltd Services, Equipment, Instruments and Karnataka Media 89 Basarass Biocon (India) Pvt Agriculture, Biofertilizers and Tamil Nadu Ltd Biopesticides 90 Baxter (India) Private Healthcare Haryana Limited 91 Bayer CropScience Ltd Agriculture, Environment, Maharashtra Biofertilizers and Biopesticides 92 Bayer Diagnostics India Healthcare, Diagnostics Gujarat Ltd. 93 Beacon Diagnostics Pvt Ltd Healthcare, Diagnostics Gujarat 94 Becton Dickinson India Pvt Healthcare, Diagnostics Haryana Ltd 95 Bejo Sheetal Seeds Pvt Ltd Agriculture, Hybrid Seeds Maharashtra 96 Bela Instruments Services, Equipment, Instruments and Maharashtra Media 97 Bench Bio Private Limited Agriculture Gujarat 98 Best Biotek Research Labs Services, Contract Research Karnataka Pvt Ltd Organization 99 Bharat Biotech Healthcare, Vaccines Andhra Pradesh International Ltd 100 Bharat Immunologicals and Healthcare, Vaccines Uttar Pradesh Biologicals Corporation Ltd (BIBCOL) 101 Bharat Petroleum Bio-energy Uttar Pradesh Corporation Ltd. 102 Bharat Serums and Healthcare, Vaccines, Recombinant Maharashtra Vaccines Ltd Therapeutics 103 Bhat Biotech India (P) Ltd Healthcare,Services, Diagnostics, Karnataka Contract Research Organization, Equipment, Instruments and Media 104 Bhawalkar Ecological Environment,Process Industries, Maharashtra Research Institute/ Bioremediation Bhawalkar Vermitech Pvt Ltd 105 BI Biotech India Pvt Ltd Services, Equipment, Instruments and New Delhi Media 106 Bigtec Labs Services, Contract Research Karnataka Organization 107 Bio Mantra Bioinformatics, Contract Research New Delhi Organization, Software Tools 108 Bio Med (P) Ltd Healthcare, Vaccines Uttar Pradesh 109 BioArc Research Solutions Services, Contract Research Gujarat Organization 110 Bioasset Technologies Services,Healthcare, Contract Maharashtra Private Limited Research Organization, Recombinant Therapeutics 111 BIOCARE RESEARCH Clinical, Food, Pharmaceuticals, Gujarat (INDIA) PVT LTD., Environmental Microbiology Solutions 112 BioCin Bioproducts Pvt Ltd Healthcare, Diagnostics Andhra Pradesh 113 Biocon Ltd Healthcare, Process Industries, Karnataka Recombinant Therapeutics, Enzymes 114 Pest Control (India) Pvt. Agriculture, Biofertilizers and Maharashtra Ltd. Biopesticides 115 BioCOS Life Sciences Bio-medical devices and instruments Karnataka Private Limited 116 Biodigital (P) Ltd Services, Equipment, Instruments and New Delhi Media 117 BioEra India Manufacture Laboratory equipments, Maharashtra instruments 118 Biogen Idec India Healthcare Haryana 119 BioGenex Life Sciences Pvt Services, Equipment, Instruments and Andhra Pradesh Ltd Media 120 Biogeniux Services, Contract Research New Delhi Organization, Equipment, Instruments and Media 121 BioGenomics Ltd biopharmaceuticals Maharashtra 122 Biogentek BG (India) Services, Equipment,
Load more

Recommended publications
  • Global Competitiveness in Pharmaceuticals
    Ref. Ares(2014)77485 - 15/01/2014 GLOBAL COMPETITIVENESS IN PHARMACEUTICALS A EUROPEAN PERSPECTIVE* * § ¨ ALFONSO GAMBARDELLA , LUIGI ORSENIGO , FABIO PAMMOLLI November 2000 Report prepared for the Enterprise Directorate-General of the European Commission * The authors wish to thank G. Baio, N. Lacetera, L. Magazzini, M. Mariani, R. Pammolli, and M. Riccaboni for skillfull research assistance. * Sant’Anna School of Advanced Studies, Pisa, [email protected]. § Bocconi University, Milan, [email protected]. ¨ Faculty of Economics Richard M. Goodwin, University of Siena, [email protected]. Enterprise Papers Enterprise Papers are a mix of policy papers, sector-specific studies, and a combination of both. Written by the staff of the Enterprise Directorate-General, or by experts working in association with them, they aim to raise awareness of enterprise policy issues and stimulate debate. These papers do not necessarily reflect the opinion or position of the European Commission. Occasional ‘special editions’ may carry communications, conference proceedings, and reports to the Council. This report was prepared for the Enterprise Directorate-General by Alfonso Gambardella, Luigi Orsenigo and Fabio Pammolli. For further information, contact European Commission Enterprise Directorate-General Information and communication unit Rue de la Loi/ Wetstraat 200 B-1049 Brussels Fax: (32-2) 299 1926 To request copies, fax (32-2) 296 9930. E-mail: [email protected] A great deal of additional information on the European Union is available on the internet. It can be accessed through the Europa server (http://europa.eu.int). Luxembourg: Office for Official Publications of the European Communities, 2001 ISBN 92-894-1071-X © European Communities, 2001 Reproduction is authorised provided the source is acknowledged.
    [Show full text]
  • “Analysis of SCM: a Case Study of Wyeth Pharmaceutical Company”
    “Analysis of SCM: A case study of Wyeth Pharmaceutical company” Submitted by: Shahzad Ali Rajpar Supervised by: Mr. Muhammad Amir Adam Program: MBA FALL 2010 National University of Computer & Emerging Science Management Science Department, Karachi, Campus Page | 1 Acknowledgments Thanks to Allah the All Merciful the all Benevolent for providing me the strength, courage, direction and skills to learn, acquire knowledge, and the ability to accept and meet challenges. Second I would like to thank all those people who have helped me in performing this research study, especially Mr. Aftab Amie Siddiqui manager planning and warehouse, Wyeth Pharmaceutical Limited Pakistan. I would like to express my sincere gratitude to my supervisor Mr. Mohammad Amir Adam for providing me his precious time, guidance, and instructions all along in order to materialize my content for the project report. I would also like to thank the FYP Coordinator Mr. Zaki Rashidi for his assistance and guidance for the research project. I am also thankful to my parents who accommodated me during those long hours of work in my project development and all the friends and colleagues who helped me out in my times of weakness and encouraged me. I am hopeful that the effort will be fruitful for the students to come in FAST after us. Once again, I am very thankful to all people who have been involved in this project report directly or indirectly. Page | 2 Table of Contents Acknowledgments ............................................................................................. 2 Table of Contents .............................................................................................. 3 CHAPTER 1 “INTRODUCTION” ........................................................................... 6 1.1 Supply chain management. ..................................................................... 6 1.2 Evolution of supply chain management.
    [Show full text]
  • PHARMACEUTICAL September 2009
    PHARMACEUTICALS September 2009 PHARMACEUTICAL September 2009 The focus of this presentation is to discuss… Market overview Policy Key trends and drivers Key players Key opportunities 2 MARKET OVERVIEW Pharmaceutical September 2009 Indian pharmaceutical market — US$ 7.3 billion opportunity • India is among the fastest growing pharmaceutical markets in the world. • The pharmaceutical market was worth US$ 16.6 billion in 2007–08; the domestic retail market is expected to cross the US$ 10 billion mark in 2010 and reach an estimated US$ 12 billion to US$ 13 billion by 2012. Domestic pharma retail market Break up of Indian pharma industry 16 13.6 13.4 14 12 10.1 10 7.7 8 5.4 4.8 6 3.9 4.1 46% (US$ million) (US$ 4 2.5 2.6 54% 1.4 2 1.1 0 2002-03 2005-06 2007-08E 2012-13P Domestic Formulation Consumption (DFC) Domestic Formulation Consumption (DFC) Total exports Formulation exports Bulk drug export Source: Pharmaceuticals: industry profile, Dec 2008, CRIS INFAC Source: Pharmaceuticals: industry profile, Dec 2008, CRIS INFAC 3 MARKET OVERVIEW Pharmaceutical September 2009 Indian pharmaceutical market — US$ 7.3 billion opportunity • The outsourcing opportunity is set to grow to Forecasted Indian pharmaceutical retail market in US$ bn US$ 53 billion in 2010 from US$ 26 billion in 2006. • Retail sales of pharmaceuticals were US$ 7.7 billion in 2007–08. • Domestic consumption accounted for nearly 46 per cent and exports for the remaining 54 per cent of total industry revenues. Source: Compiled from industry sources 4 MARKET OVERVIEW Pharmaceutical September 2009 Anti-infectives — largest therapeutic category • The anti-infectives segment was the highest contributor (18 per cent) to total domestic sales in 2007–08.
    [Show full text]
  • Directory of Recognised In-House R&D Units
    DIRECTORY OF RECOGNISED IN-HOUSE R&D UNITS 2011 DEPARTMENT OF SCIENTIFIC & INDUSTRIAL RESEARCH MINISTRY OF SCIENCE AND TECHNOLOGY NEW DELHI Sl.No Registration Name and Address of the Firm Location of R&D Unit Recognition Number Valid Upto 1 TU/IV-RD/3105 20 Microns Nano Minerals Limited 11, GIDC Estate, Waghodia, 31.03.2013 307-308, Arundeep Complexes.Race Dist. Vadodrara, Gujrat Course ,Vadodara-390007, Gujarat 2 TU/IV-RD/3351 A.J Organica Pvt. Ltd. Plot . No 8 Survey No. 288 31.03.2014 Plot . No 8Survey No. 288,Raisoni Raisoni Indsutrial Estate Mann Indsutrial Estate Mann Taluka Mulshi Taluka Mulshi Hinjewadi Phase IIPune- 411057 3 TU/IV-RD/3153 Aadhaar Seeds Pvt. Ltd. Raja Bollaram (Village), 31.03.2014 1-5-12/2/2, New Maruthi Nagar, Medchal (Mandal), R. R. Dist. Kothapet, Hyderabad – 500 035 (AP) 4 TU/IV-RD/2141 Aarti Drugs Ltd. (i) Plot No.198, MIDC Tarapur, 31.03.2014 D-109, Gr. Floor, Mahendra Indl. Vill. Pamtembhi, Tal. Palghar, EstateRoad No. 29, Sion (E)Mumbai - Dist. Thane (ii) G-60, MIDC, 400 022 Tarapur, Tal. Palghar, Dist. Thane 5 TU/IV-RD/2193 Aarti Industries Ltd. Plot No.801, 801/23, GIDC 31.03.2012 Udyog Kshetra, 2nd FloorMulund- Estate, Phase III, Vapi, Dist. Goregaon Link Road, Mulund Valsad, Gujarat (W)Mumbai-400080 6 TU/IV-RD/637 Abbott India Ltd. L-18, Verna Ind. Area, Verna, 31.03.2013 3-4, Corporate ParkSion-Trombay Salcette, Goa Road,Chembur,Mumbai- 400071 7 TU/IV-RD/3180 ABC Genomics (India) Pvt. Ltd.
    [Show full text]
  • Federal Register/Vol. 77, No. 115/Thursday, June 14, 2012
    Federal Register / Vol. 77, No. 115 / Thursday, June 14, 2012 / Notices 35691 TABLE 1—LIST OF SAFETY AND EFFECTIVENESS SUMMARIES FOR APPROVED PMAS MADE AVAILABLE FROM JANUARY 1, 2012, THROUGH MARCH 31, 2012—Continued PMA No., Docket No. Applicant Trade name Approval date P060008.S046, FDA–2012–M–0210 ... Boston Scientific Corp ......................... TAXUS Liberte´ Paclitaxel-Eluting Cor- February 22, 2012. onary Stent System (Monorail and Over-The-Wire Delivery Systems). P030025.S086, FDA–2012–M–0209 ... Boston Scientific Corp ......................... TAXUS Express2 Paclitaxel-Eluting February 22, 2012. Coronary Stent System (Monorail and Over-The-Wire Delivery Sys- tems). P110023, FDA–2012–M–0221 ............ ev3, Inc ................................................ Everflex Self-Expanding Peripheral March 7, 2012. Stent System (Everflex). P070004, FDA–2012–M–0250............ Sientra, Inc.......................................... SIENTRA Silicone Gel Breast Im- March 9, 2012. plants. II. Electronic Access LOCATION: The meeting will be held at submissions. In the process of Persons with access to the Internet the FDA White Oak Campus, 10903 considering these changes, FDA has may obtain the documents at http:// New Hampshire Ave., Bldg. 31 previously made available for comment www.fda.gov/MedicalDevices/ Conference Center, Great Room 1503, versions of documents that support ProductsandMedicalProcedures/ Silver Spring, MD 20993. The following making regulatory submissions in DeviceApprovalsandClearances/ link contains public meeting attendee electronic format using the (eCTD) information as well as frequently asked PMAApprovals/default.htm and http:// specifications. These draft documents questions and answers regarding public www.fda.gov/MedicalDevices/ represented FDA’s major updates to meetings at White Oak: http:// ProductsandMedicalProcedures/ Module 1 of the eCTD based on www.fda.gov/AboutFDA/ DeviceApprovalsandClearances/ previous comments.
    [Show full text]
  • WO 2012/068299 A9 24 May 2012 (24.05.2012) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) CORRECTED VERSION (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2012/068299 A9 24 May 2012 (24.05.2012) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 31/519 (2006.01) A61K 31/53 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/551 7 (2006.0 1) A61P 17/00 (2006.0 1) AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, (21) International Application Number: DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, PCT/US201 1/061062 HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, (22) International Filing Date: KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, 16 November 201 1 (16.1 1.201 1) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, (25) Filing Language: English SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, (26) Publication Language: English TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: (84) Designated States (unless otherwise indicated, for every 61/414,334 16 November 2010 (16. 11.2010) US kind of regional protection available): ARIPO (BW, GH, 61/414,348 16 November 2010 (16.
    [Show full text]
  • REGISTER of SPONSORS (Tiers 2 & 5 and Sub Tiers Only)
    REGISTER OF SPONSORS (Tiers 2 & 5 and Sub Tiers Only) DATE: 09-January-2017 Register of Sponsors Licensed Under the Points-based System This is a list of organisations licensed to sponsor migrants under Tiers 2 & 5 of the Points-Based System. It shows the organisation's name (in alphabetical order), the sub tier(s) they are licensed for, and their rating against each sub tier. A sponsor may be licensed under more than one tier, and may have different ratings for each tier. No. of Sponsors on Register Licensed under Tiers 2 and 5: 29,794 Organisation Name Town/City County Tier & Rating Sub Tier ?What If! Ltd London Tier 2 (A rating) Tier 2 General Tier 2 (A rating) Intra Company Transfers (ICT) @ Home Accommodation Services Ltd London Tier 2 (A rating) Tier 2 General Tier 5 (A rating) Creative & Sporting ]performance s p a c e [ london london Tier 5 (A rating) Creative & Sporting 01 Telecom Limited Brighton Tier 2 (A rating) Tier 2 General 0-two Maintenance London Tier 2 (A rating) Tier 2 General 1 Stop Print Ltd Ilford Tier 2 (A rating) Tier 2 General 1 Tech LTD London Tier 2 (A rating) Tier 2 General 10 Europe Limited Edinburgh Tier 2 (A rating) Tier 2 General Tier 2 (A rating) Intra Company Transfers (ICT) 10 GROUP LTD T/A THE 10 GROUP LONDON Tier 2 (A rating) Tier 2 General 10 Minutes With Limited London Tier 2 (A rating) Tier 2 General Page 1 of 1952 Organisation Name Town/City County Tier & Rating Sub Tier 1000heads Ltd London Tier 2 (A rating) Tier 2 General 1000mercis LTD London Tier 2 (A rating) Tier 2 General 100Starlings Ltd
    [Show full text]
  • Drugs and Pharmaceuticals "D".Pdf
    Drugs and Pharmaceuticals “D” NDC Code Description Manufacturer Basic Category UM 63323-0127-10 DACARBAZINE PR 100MG 10VL APP-AMER PHARM PTNRS CT Injectables/RX Drugs 63323-0128-20 DACARBAZINE PR 200MG 10VL APP-AMER PHARM PTNRS CT Injectables/RX Drugs 58768-0727-15 DACRIOSE 15ML NVR DR NOVARTIS OPHTHALMICS EA OTC 58768-0727-20 DACRIOSE DR 120ML NOVARTIS OPHTHALMICS EA OTC 10135-0115-01 DAILY MULTIPLE VIT RED 100 MARLEX PHARMACEUTICALS EA OTC 63739-0274-01 DAILY MULTI/IRON 750UD INST SKY PHARMACEUTICALS BX OTC 63739-0068-01 DAILY MULTIVITAMIN 750UD SKY PHARMACEUTICALS EA OTC INST 63739-0274-03 DAILY MULTIVTMN/IRON 25x30 SKY PHARMACEUTICALS BX OTC UDPC 00536-0410-59 DAILY VIT HOMOGEN 8oz SR WATSON LABS EA OTC 00536-3546-10 DAILY VIT IRON 1000 WAT TB WATSON LABS EA OTC 00536-3546-01 DAILY-VIT/IRON 100 WAT WATSON LABS EA OTC 00436-0946-16 DAKINS FS 0.5% 480ML NR SL CENTURY PHARMACEUTICALS EA OTC 50383-0624-16 DALYVITE 16oz SL HI-TECH PHARMACAL EA OTC COMPANY 49938-0101-01 DAPSONE 100MG 100 TB JACOBUS PHARMACEUTICAL EA Injectables/RX Drugs CO. INC 49938-0102-01 DAPSONE 25MG 100 TB JACOBUS PHARMACEUTICAL EA Injectables/RX Drugs CO. INC 00173-0201-55 DARAPRIM 25MG 100 GLX TB GLAXOSMITHKLINE EA Injectables/RX Drugs 00002-0363-02 DARVOCENT-N 100 TB 100 C4 TB A. A. I PHARMACEUTICALS EA Drug, DEA Schedule 00002-0363-33 DARVOCENT-N 100 TB 100UD C4 A. A. I PHARMACEUTICALS EA Drug, DEA Schedule TB 00002-0803-02 DARVON CP 65MG 100 C4 CP A.
    [Show full text]
  • Redacted Craig Mccann Opioid MDL ARCOS Report.Pdf
    Case: 1:17-md-02804-DAP Doc #: 1999-13 Filed: 07/25/19 1 of 154. PageID #: 264837 Confidential - Subject to Protective Order IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF OHIO EASTERN DIVISION IN RE NATIONAL : MDL No. 2804 PRESCRIPTION OPIATE : CASE NO. 17-MD-2804 LITIGATION : (DAP) : EXPERT REPORT OF CRAIG J. MCCANN, PH.D., CFA March 25, 2019 Case: 1:17-md-02804-DAP Doc #: 1999-13 Filed: 07/25/19 2 of 154. PageID #: 264838 Confidential - Subject to Protective Order Table of Contents I. Qualifications and Remuneration ..................................................... - 1 - A. Qualifications ......................................................................... - 1 - B. Remuneration ......................................................................... - 2 - II. Materials Reviewed .......................................................................... - 2 - III. Assignment ....................................................................................... - 4 - IV. Summary of Opinions ....................................................................... - 4 - V. ARCOS Data .................................................................................... - 7 - A. Receipt of ARCOS Data from the DEA ................................ - 7 - B. ARCOS Data Fields Produced by DEA ................................. - 9 - 1. Seller DEA Number .................................................................. - 11 - 2. Seller Business Activity ............................................................ - 12
    [Show full text]
  • Torreya In-Depth Study—The Future of the Global Pharmaceutical Industry
    The Future of the Global Pharmaceutical Industry October 2017 Ta b l e o f Co n te n t s Section Page 1. Executive Summary 3 2. Pharmaceutical Sector Has Grown Rapidly in the Last Century 7 - Widespread concerns about the sector today 8 - Thousandfold increase in value of companies in sector since 1920s 10 3. Pharmaceutical Sector Will Triple in Size in the Next 40 Years 12 - Pharmaceutical consumption econometrically close related to GDP growth 14 - Based upon expected GDP growth, the pharma sector will likely triple in size by 2060 19 4. Total Value of the Pharmaceutical Sector Today over $5 Trillion 20 - Total revenue in the pharma sector around $1.1 trillion in 2017 23 - Total value of companies in sector over $5 trillion. Pharma one of the world’s largest sectors 24 5. Pharma Will Be Positively Impacted by Growth in Rare Disease Drugs and China 27 - Cost controls widespread and likely to continue. Major impact on Europe market 28 - Rare disease pharma sector has grown in value by 1300% since 2000. To continue growing fast 37 - China to become a close #2 to the U.S. market in time. Dramatic growth to continue 49 6. Innovations in Inflammation Control, Nucleic Acids and Implantables Will Transform Industry 55 - Better Manufacture Will Facilitate Dramatic Growth in Peptide Therapeutics 56 - Control of Inflammation May Substantially Reduce Mortality from Cancer & Heart Disease 61 - Nucleic Acid Therapeutics a Source of Substantial Future Growth 65 - Cell Therapy is Becoming Mainstream in the Pharmaceutical Industry 70 - Implantables and Electroceuticals Will Redefine Therapeutic Sector 74 7.
    [Show full text]
  • Final Report Ventura County Medical Center 340B Drug Pricing Program
    Ventura County Grand Jury 2017 - 2018 Final Report Ventura County Medical Center 340B Drug Pricing Program April 26, 2018 This page intentionally blank Ventura County 2017 – 2018 Grand Jury Final Report Ventura County Medical Center 340B Drug Pricing Program Summary The 2017-2018 Ventura County Grand Jury (Grand Jury) opened an investigation after receiving a complaint about the Ventura County Medical Center’s (VCMC) 340B Drug Pricing Program (340B program). The 340B program requires pharmaceutical companies to provide prescription drugs at significant discounts to hospitals and clinics serving large numbers of low-income patients. In July 2015 an audit of VCMC was conducted by the federal Health Resources and Services Administration (HRSA). The audit discovered that VCMC received duplicate discounts on medications in the 340B program. A total of 107 pharmaceutical companies were affected by the duplicate discount billing. The total duplicate discounts were in excess of $3 million. The Grand Jury concluded there was inadequate oversight of the VCMC 340B program prior to the HRSA audit. This resulted in VCMC being required to reimburse pharmaceutical companies at least $861,000 and potentially as much as $1.6 million. The Grand Jury concluded while VCMC conducts its own in-house audits of the 340B program, more critical audits should be conducted by an independent outside party. The Grand Jury recommends VCMC consider bringing in outside resources with extensive 340B program experience to assist in the supervision of a corrective action plan. The Grand Jury also recommends VCMC request the Ventura County Auditor-Controller conduct regular compliance audits of the 340B program.
    [Show full text]
  • Global Competitiveness in Pharmaceuticals: a European Perspective
    Munich Personal RePEc Archive Global Competitiveness in Pharmaceuticals: A European Perspective Gambardella, Alfonso and Orsenigo, Luigi and Pammolli, Fabio IMT Institute For Advanced Studies, Lucca 1 November 2000 Online at https://mpra.ub.uni-muenchen.de/15965/ MPRA Paper No. 15965, posted 30 Jun 2009 09:08 UTC - GLOBAL COMPETITIVENESS IN PHARMACEUTICALS A EUROPEAN PERSPECTIVE* ∗ ♣ ♦ ALFONSO GAMBARDELLA , LUIGI ORSENIGO , FABIO PAMMOLLI November 2000 Report Prepared for the Directorate General Enterprise of the European Commission * The authors wish to thank G. Baio, N. Lacetera, L. Magazzini, M. Mariani, R. Pammolli, and M. Riccaboni for skillfull research assistance. ∗ Sant’Anna School of Advanced Studies, Pisa, [email protected]. ♣ Bocconi University, Milan, [email protected]. ♦ Faculty of Economics Richard M. Goodwin, University of Siena, [email protected]. I. INTRODUCTION............................................................................................... 2 II. STRUCTURAL INDICATORS IN THE EU, USA, AND JAPAN.................. 11 III. THE EUROPEAN AND US MULTINATIONALS: COMPARATIVE PERFORMANCE ...................................................................................................... 25 IV. R&D AND INNOVATION AS SOURCES OF COMPETITIVE ADVANTAGES.......................................................................................................... 36 IV.1 THE DIVISION OF INNOVATIVE LABOUR IN PHARMACEUTICALS ....................... 36 IV.2 THE US AS AN INCREASINGLY PREFERRED LOCATION FOR
    [Show full text]